PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
23190689-7	2013	Plasma renin activity was significantly augmented in the valsartan-treated group, and it was significantly attenuated in the valsartan+cilnidipine-treated group.	Valsartan	57-66	renin	Rattus norvegicus	7-12	
20685818-8	2010	Combination therapy and monotherapy of valsartan and aliskiren had a comparable enhancing effect on the mRNA expression of renin, whereas all these treatments did not affect the expression of the (pro)renin receptor.	Valsartan	39-48	renin	Rattus norvegicus	123-128	
23318498-8	2013	Valsartan (10(-8)M) dialyzed together with renin (120pM) into the cell decreased drastically the effect of renin on potassium current.	Valsartan	0-9	renin	Rattus norvegicus	43-48	
23318498-8	2013	Valsartan (10(-8)M) dialyzed together with renin (120pM) into the cell decreased drastically the effect of renin on potassium current.	Valsartan	0-9	renin	Rattus norvegicus	107-112	
23318498-9	2013	An increment of potassium current was also found when intracellular renin was dialyzed into cardiomyocytes exposed to Krebs solution containing valsartan (10(-8)M) for 10min prior to renin administration.	Valsartan	144-153	renin	Rattus norvegicus	68-73	
23318498-13	2013	The effect of renin on total potassium currents was inhibited by valsartan and by Bis-1.	Valsartan	65-74	renin	Rattus norvegicus	14-19	
21293118-6	2011	Cilnidipine suppressed the increase in plasma renin activity and plasma Ang II levels induced by valsartan, but amlodipine did not.	Valsartan	97-106	renin	Rattus norvegicus	46-51	
15534073-6	2005	Similarly, renal renin content and PRC increased in response to LS and increased further in response to combined LS and valsartan or PD administration.	Valsartan	120-129	renin	Rattus norvegicus	17-22	
17670863-4	2007	LNa(+), VAL, PD, l-NAME, and ODQ increased RRC, ANG II, and renin mRNA.	Valsartan	8-11	renin	Rattus norvegicus	60-65	
17670863-7	2007	Combined treatment with PD, l-NAME, or ODQ and VAL reversed the effects of VAL and caused further increase in RRC, ANG II, renin mRNA, and protein.	Valsartan	47-50	renin	Rattus norvegicus	123-128	
17670863-7	2007	Combined treatment with PD, l-NAME, or ODQ and VAL reversed the effects of VAL and caused further increase in RRC, ANG II, renin mRNA, and protein.	Valsartan	75-78	renin	Rattus norvegicus	123-128	
10792607-11	2000	The beneficial effects afforded by valsartan therapy strengthen the importance of the local renin-angiotensin system in mediating progressive diabetic renal injury.	Valsartan	35-44	renin	Rattus norvegicus	92-97	
31030610-12	2019	Maximal blockade of the renin-angiotensin system, achieved by valsartan+siRNA, yielded the greatest reduction in blood pressure and cardiac hypertrophy, whereas AGT lowering alone was as effective as conventional renin-angiotensin system inhibitors.	Valsartan	62-71	renin	Rattus norvegicus	24-29	
35197849-9	2021	Moreover, sacubitril/valsartan therapy increased plasma renin and did not prevent HSD-induced increases in renal angiotensin II, while sacubitril/C21 completely prevented these changes.	Valsartan	21-30	renin	Rattus norvegicus	56-61	
31096810-0	2019	Valsartan chronotherapy reverts the non-dipper pattern and improves blood pressure control through mediation of circadian rhythms of the renin-angiotensin system in spontaneous hypertension rats.	Valsartan	0-9	renin	Rattus norvegicus	137-142